The pathogenesis of neurodegeneration in diabetic retinopathy and potential therapeutic approaches

doi:10.3877/cma.j.issn.2095-655X.2023.02.010

Abstract

Abstract:

Diabetic retinopathy is one of the most common diabetes complications and the leading cause of blindness in the working-age population worldwide. Diabetic retinopathy can cause progressive retinal damage, eventually leading to the vision loss and lowering the patient′s quality of life.In the past, diabetic retinopathy was considered to be only a vascular disease. However, it is now widely believed that diabetic retinopathy is a neurovascular disease with neurodegeneration occurring prior to the appearance of the microvascular lesions. Although diabetic retinopathy has been extensively studied, its complex pathogenesis has not been fully elucidated, and this review focuses on the possible pathogenesis of neurodegeneration in diabetic retinopathy as well as potential treatments.

Key words: Diabetic retinopathy, Neurodegenerative diseases, Neuroglial cell, Glutamic acid, Neuroprotective factor

Qiyu Ran, Huaipeng Tang, Lei Kong, Bing Sun. The pathogenesis of neurodegeneration in diabetic retinopathy and potential therapeutic approaches[J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(02): 120-124.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2023.02.010

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2023/V11/I02/120

References 43

[1]	Jindal V．Neurodegeneration as a primary change and role of neuroprotection in diabetic retinopathy[J].Mol Neurobiol，2015，51(3)：878-884.DOI：10.1007/s12035-014-8732-7.
[2]	Ogurtsova K，da Rocha Fernandes JD，Huang Y，et al.IDF diabetes stlas：global estimates for the prevalence of diabetes for 2015 and 2040[J].Diabetes Res Clin Pract，2017(128)：40-50.DOI：10.1016/j.diabres.2017.03.024.
[3]	Tavares Ferreira J，Alves M，Dias-Santos A，et al.Retinal neurodegeneration in diabetic patients without diabetic retinopathy[J].Invest Ophthalmol Vis Sci，2016，57(14)：6455-6460.DOI：10.1167/iovs.16-20215.
[4]	Narayanan SP，Shosha E，D Palani C．Spermine oxidase：a promising therapeutic target for neurodegeneration in diabetic retinopathy[J].Pharmacol Res，2019(147)：104299.DOI：10.1016/j.phrs.2019.104299.
[5]	Satue M，Cipres M，Melchor I，et al.Ability of swept source OCT technology to detect neurodegeneration in patients with type 2 diabetes mellitus without diabetic retinopathy[J].Jpn J Ophthalmol，2020，64(4)：367-377.DOI：10.1007/s10384-020-00729-0.
[6]	Toprak I，Fenkci SM，Fidan Yaylali G，et al.Early retinal neurodegeneration in preclinical diabetic retinopathy：a multifactorial investigation[J].Eye (Lond)，2020，34(6)：1100-1107.DOI：10.1038/s41433-019-0646-1.
[7]	Garcia-Ramírez M，Hernández C，Villarroel M，et al.Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy[J].Diabetologia，2009，52(12)：2633-2641.DOI：10.1007/s00125-009-1548-8.
[8]	Wang W，Lo A．Diabetic retinopathy：pathophysiology and treatments[J].Int J Mol Sci，2018，19(6)：1816.DOI：10.3390/ijms19061816.
[9]	Solomon SD，Chew E，Duh EJ，et al.Diabetic retinopathy：a position statement by the American Diabetes Association[J].Diabetes Care，2017，40(3)：412-418.DOI：10.2337/dc16-2641.
[10]	Antonetti DA，Klein R，Gardner TW.Diabetic retinopathy[J].N Engl J Med，2012，366(13)：1227-1239.DOI：10.1056/NEJMra1005073.
[11]	Simó R, Stitt AW, Gardner TW. Neurodegeneration in diabetic retinopathy：does it really matter？[J].Diabetologia，2018，61(9)：1902-1912.DOI：10.1007/s00125-018-4692-1.
[12]	Simó R，Simó-Servat O，Bogdanov P，et al.Diabetic Retinopathy：role of neurodegeneration and therapeutic perspectives[J].Asia Pac J Ophthalmol (Phila)，2022，11(2)：160-167.DOI：10.1097/APO.0000000000000510.
[13]	Sohn EH，van Dijk HW，Jiao C，et al.Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus[J].Proc Natl Acad Sci U S A，2016，113(19)：E2655-E2664.DOI：10.1073/pnas.1522014113.
[14]	Sabry D, Abdelhady I, Abouelkheir HY, et al. Sites of highest predictability for neurodegeneration in patients with type 2 diabetes mellitus without diabetic retinopathy[J].Int Ophthalmol，2021，41(5)：1883-1893.DOI：10.1007/s10792-021-01750-z.
[15]	van de Kreeke JA，Darma S，Chan Pin Yin J，et al.The spatial relation of diabetic retinal neurodegeneration with diabetic retinopathy[J].PLoS One，2020，15(4)：e0231552.DOI：10.1371/journal.pone.0231552.
[16]	冉启玉，杜鹏宇，孔蕾，等．神经酰胺与糖尿病及其并发症关系研究进展[J/CD].中华诊断学电子杂志，2022，10(3)：158-162.DOI：10.3877/cma.j.issn.2095-655X.2022.03.003.
[17]	Wong TY，Cheung CM，Larsen M，et al.Diabetic retinopathy[J].Nat Rev Dis Primers，2016(2)：16012.DOI：10.1038/nrdp.2016.12.
[18]	Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy[J].Int J Mol Sci，2018，19(4)：942.DOI：10.3389/fimmu.2020.583687.
[19]	Ola MS, Al-Dosari D, Alhomida AS. Role of oxidative stress in diabetic retinopathy and the beneficial effects of flavonoids[J].Curr Pharm Des，2018，24(19)：2180-2187.DOI：10.2174/1381612824666180515151043.
[20]	Sorrentino FS，Allkabes M，Salsini G，et al.The importance of glial cells in the homeostasis of the retinal microenvironment and their pivotal role in the course of diabetic retinopathy[J].Life Sci，2016(162)：54-59.DOI：10.1016/j.lfs.2016.08.001.
[21]	Ramirez AI，de Hoz R，Salobrar-Garcia E，et al.The role of microglia in retinal neurodegeneration：Alzheimer's disease，Parkinson，and Glaucoma[J].Front Aging Neurosci，2017(9)：214.DOI：10.3389/fnagi.2017.00214.
[22]	Altmann C，Schmidt M．The role of microglia in diabetic retinopathy：inflammation，microvasculature defects and neurodegeneration[J].Int J Mol Sci，2018，19(1).DOI：10.3390/ijms19010110.
[23]	Rolev KD, Shu XS, Ying Y. Targeted pharmacotherapy against neurodegeneration and neuroinflammation in early diabetic retinopathy[J].Neuropharmacology，2021(187)：108498.DOI：10.1016/j.neuropharm.2021.108498.
[24]	Nogueira TC，Paula FM，Villate O，et al.GLIS3，a susceptibility gene for type 1 and type 2 diabetes，modulates pancreatic beta cell apoptosis via regulation of a splice variant of the BH3-only protein Bim[J].PLoS Genet，2013，9(5)：e1003532.DOI：10.1371/journal.pgen.1003532.
[25]	Kadłubowska J，Malaguarnera L，Wz· P，et al.Neurodegeneration and neuroinflammation in diabetic retinopathy：potential approaches to delay neuronal loss[J].Curr Neuropharmacol，2016，14(8)：831-839.DOI：10.2174/1570159x14666160614095559.
[26]	Soni D，Sagar P，Takkar B．Diabetic retinal neurodegeneration as a form of diabetic retinopathy[J].Int Ophthalmol，2021，41(9)：3223-3248.DOI：10.1007/s10792-021-01864-4.
[27]	Zhang Y，Bhavnani BR.Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by equine estrogens[J].BMC Neurosci，2006(7)：49.DOI：10.1186/1471-2202-7-49.
[28]	Le YZ.VEGF production and signaling in Müller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases[J].Vision Res，2017(139)：108-114.DOI：10.1016/j.visres.2017.05.005.
[29]	Froger N，Matonti F，Roubeix C，et al.VEGF is an autocrine/paracrine neuroprotective factor for injured retinal ganglion neurons[J].Sci Rep，2020，10(1)：12409.DOI：10.1038/s41598-020-68488-z.
[30]	Usui-Ouchi A，Friedlander M．Anti-VEGF therapy：higher potency and long-lasting antagonism are not necessarily better[J].J Clin Invest，2019，129(8)：3032-3034.DOI：10.1172/JCI129862.
[31]	Unung PJ，Bassey IE，Etukudo MH，et al.Effect of glycemic control and dyslipidemia on plasma vascular endothelial growth factor and pigment epithelium-derived factor in diabetic retinopathy patients in Northern Nigeria[J].Int J Health Sci (Qassim)，2020，14(6)：4-12.
[32]	Simó-Servat O，Hernández C，Simó R．Somatostatin and diabetic retinopathy：an evolving story[J].Endocrine，2018，60(1)：1-3.DOI：10.1007/s12020-018-1561-0.
[33]	Elkjaer AS，Lynge SK，Grauslund J．Evidence and indications for systemic treatment in diabetic retinopathy：a systematic review[J].Acta Ophthalmol，2020，98(4)：329-336.DOI：10.1111/aos.14377.
[34]	Kutlutürk Karagöz I，Allahverdiyev A，Baǧırova M，et al.Current approaches in treatment of diabetic retinopathy and future perspectives[J].J Ocul Pharmacol Ther，2020，36(7)：487-496.DOI：10.1089/jop.2019.0137.
[35]	Fragiotta S，Pinazo-Durán MD，Scuderi G．Understanding neurodegeneration from a clinical and therapeutic perspective in early diabetic retinopathy[J].Nutrients，2022，14(4)：792.DOI：10.3390/nu14040792.
[36]	Parisi V，Oddone F，Ziccardi L，et al.Citicoline and retinal ganglion cells：effects on morphology and function[J].Curr Neuropharmacol，2018，16(7)：919-932.DOI：10.2174/1570159X15666170703111729.
[37]	Faiq MA，Wollstein G，Schuman JS，et al.Cholinergic nervous system and glaucoma：from basic science to clinical applications[J].Prog Retin Eye Res，2019(72)：100767.DOI：10.1016/j.preteyeres.2019.06.003.
[38]	Parravano M，Scarinci F，Parisi V，et al.Citicoline and vitamin B(12) eye drops in type 1 diabetes：results of a 3-year pilot study evaluating morpho-functional retinal changes[J].Adv Ther，2020，37(4)：1646-1663.DOI：10.1007/s12325-020-01284-3.
[39]	Parisi V，Ziccardi L，Barbano L，et al.Citicoline and vitamin B(12) eye drops in type 1diabetes：results of a 36-month pilot study evaluating macular electrophysiological changes[J].Adv Ther，2021，38(7)：3924-3936.DOI：10.1007/s12325-021-01771-1.
[40]	Kusari J，Zhou S，Padillo E，et al.Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats[J].Invest Ophthalmol Vis Sci，2007，48(11)：5152-5159.DOI：10.1167/iovs.07-0427.
[41]	Santos AR，Ribeiro L，Bandello F，et al.Functional and structural findings of neurodegeneration in early stages of diabetic retinopathy：cross-sectional analyses of baseline data of the EUROCONDOR project[J].Diabetes，2017，66(9)：2503-2510.DOI：10.2337/db16-1453.
[42]	Simó R，Hernández C，Porta M，et al.Effects of topically administered neuroprotective drugs in early stages of diabetic retinopathy：results of the EUROCONDOR clinical trial[J].Diabetes，2019，68(2)：457-463.DOI：10.2337/db18-0682.
[43]	Grauslund J，Frydkjaer-Olsen U，Peto T，et al.Topical treatment with brimonidine and somatostatin causes retinal vascular dilation in patients with early diabetic retinopathy from the EUROCONDOR[J].Invest Ophthalmol Vis Sci，2019，60(6)：2257-2262.DOI：10.1167/iovs.18-26487.

Please choose a citation manager

Content to export